Revelation of the IFNα, IL-10, IL-8 and IL-1β as promising biomarkers reflecting immuno-pathological mechanisms in porcine Huntington's disease model

Journal of Neuroimmunology

Volumn 293, Issue , 2016, Pages 71-81

  Valekova, Ivona ^a,b,c   Jarkovska, Karla ^a,b,e   Kotrcova, Eva ^a,b,c   Bucci, John ^d   Ellederova, Zdenka ^a,b   Juhas, Stefan ^a,b   Motlik, Jan ^a,b   Gadher, Suresh Jivan ^d   Kovarova, Hana ^a,b  

^a INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS   (Czech Republic)

^b Research Center PIGMOD   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d Thermo Fisher Scientific   (United States)

^e ChemAxon sro   (Czech Republic)

Author keywords

Biomarker(s); Central nervous system; Cytokines; Immune response; Porcine Huntington's disease model; Serum

Indexed keywords

ALPHA INTERFERON; CYTOKINE; HUNTINGTIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 8; AIF1 PROTEIN, HUMAN; BIOLOGICAL MARKER; DNA BINDING PROTEIN; HTT PROTEIN, HUMAN; LIPOPOLYSACCHARIDE; NERVE PROTEIN;

ANALYSIS OF VARIANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCEPTUAL FRAMEWORK; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MARKER; HUNTINGTON CHOREA; IMMUNOPATHOLOGY; IMMUNOPHENOTYPING; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; UBIQUITINATION; ANIMAL; CELL CULTURE; CENTRAL NERVOUS SYSTEM; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MINIPIG; MONOCYTE; PATHOLOGY; PIG; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BIOMARKERS; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM; CYTOKINES; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; HUMANS; HUNTINGTON DISEASE; INTERFERON-ALPHA; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; MICROGLIA; MONOCYTES; NERVE TISSUE PROTEINS; SWINE; SWINE, MINIATURE;

EID: 84959345560     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2016.02.012     Document Type: Article

References (37)

1. Anon. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983.
2. Aylward E.H., Sparks B.F., Field K.M., Yallapragada V., Shpritz B.D., Rosenblatt A., Brandt J., Gourley L.M., Liang K., Zhou H., Margolis R.L., Ross C.A. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004, 63:66-72.
3. Baxa M., Hruska-Plochan M., Juhas S., Vodicka P., Pavlok A., Juhasova J., Miyanohara A., Nejime T., Klima J., Macakova M., Marsala S., Weiss A., Kubickova S., Musilova P., Vrtel R., Sontag E.M., Thompson L.M., Schier J., Hansikova H., Howland D.S., Cattaneo E., DiFiglia M., Marsala M., Motlik J. A transgenic minipig model of Huntington's disease. J. Huntington's Dis. 2013, 2:47-68.
4. Bendixen E., Danielsen M., Larsen K., Bendixen C. Advances in porcine genomics and proteomics-a toolbox for developing the pig as a model organism for molecular biomedical research. Brief. Funct. Genomics 2010, 9:208-219.
5. Bjorkqvist M., Wild E.J., Thiele J., Silvestroni A., Andre R., Lahiri N., Raibon E., Lee R.V., Benn C.L., Soulet D., Magnusson A., Woodman B., Landles C., Pouladi M.A., Hayden M.R., Khalili-Shirazi A., Lowdell M.W., Brundin P., Bates G.P., Leavitt B.R., Moller T., Tabrizi S.J. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med. 2008, 205:1869-1877.
6. Brown K.R., Jurisica I. Online predicted human interaction database. Bioinformatics 2005, 21:2076-2082.
7. Chang K.H., Wu Y.R., Chen Y.C., Chen C.M. Plasma inflammatory biomarkers for Huntington's disease patients and mouse model. Brain Behav. Immun. 2015, 44:121-127.
8. Cui L., Jeong H., Borovecki F., Parkhurst C.N., Tanese N., Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006, 127:59-69.
9. Dalrymple A., Wild E.J., Joubert R., Sathasivam K., Bjorkqvist M., Petersen A., Jackson G.S., Isaacs J.D., Kristiansen M., Bates G.P., Leavitt B.R., Keir G., Ward M., Tabrizi S.J. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J. Proteome Res. 2007, 6:2833-2840.
10. Deutsch M., Papatheodoridis G.V., Tzakou A., Hadziyannis S.J. Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 2008, 20:5-9.
11. Dobson L., Trager U., Farmer R., Hayardeny L., Loupe P., Hayden M.R., Tabrizi S.J. Laquinimod dampens hyperactive cytokine production in huntington's disease patient myeloid cells. J. Neurochem. 2016, (Jan 29, Epub ahead of print). 10.1111/jnc.13553.
12. Fu J., Jin J., Cichewicz R.H., Hageman S.A., Ellis T.K., Xiang L., Peng Q., Jiang M., Arbez N., Hotaling K., Ross C.A., Duan W. Trans-(-)-epsilon-viniferin increases mitochondrial sirtuin 3 (SIRT3), activates AMP-activated protein kinase (AMPK), and protects cells in models of Huntington disease. J. Biol. Chem. 2012, 287:24460-24472.
13. Giralt A., Puigdellivol M., Carreton O., Paoletti P., Valero J., Parra-Damas A., Saura C.A., Alberch J., Gines S. Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity. Hum. Mol. Genet. 2012, 21:1203-1216.
14. Gitik M., Liraz-Zaltsman S., Oldenborg P.A., Reichert F., Rotshenker S. Myelin down-regulates myelin phagocytosis by microglia and macrophages through interactions between CD47 on myelin and SIRPalpha (signal regulatory protein-alpha) on phagocytes. J. Neuroinflammation 2011, 8:24.
15. Gottschalk P.G., Dunn J.R. The five-parameter logistic: a characterization and comparison with the four-parameter logistic. Anal. Biochem. 2005, 343:54-65.
16. Guillemin G., Boussin F.D., Croitoru J., Franck-Duchenne M., Le Grand R., Lazarini F., Dormont D. Obtention and characterization of primary astrocyte and microglial cultures from adult monkey brains. J. Neurosci. Res. 1997, 49:576-591.
17. Hengel H., Koszinowski U.H., Conzelmann K.K. Viruses know it all: new insights into IFN networks. Trends Immunol. 2005, 26:396-401.
18. Ionescu V.A., Villanueva E.B., Hashioka S., Bahniwal M., Klegeris A. Cultured adult porcine astrocytes and microglia express functional interferon-gamma receptors and exhibit toxicity towards SH-SY5Y cells. Brain Res. Bull. 2011, 84:244-251.
19. Jeong H., Cohen D.E., Cui L., Supinski A., Savas J.N., Mazzulli J.R., Yates J.R., Bordone L., Guarente L., Krainc D. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat. Med. 2012, 18:159-165.
20. Jiang H., Poirier M.A., Liang Y., Pei Z., Weiskittel C.E., Smith W.W., DeFranco D.B., Ross C.A. Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin. Neurobiol. Dis. 2006, 23:543-551.
21. Jiang M., Wang J., Fu J., Du L., Jeong H., West T., Xiang L., Peng Q., Hou Z., Cai H., Seredenina T., Arbez N., Zhu S., Sommers K., Qian J., Zhang J., Mori S., Yang X.W., Tamashiro K.L., Aja S., Moran T.H., Luthi-Carter R., Martin B., Maudsley S., Mattson M.P., Cichewicz R.H., Ross C.A., Holtzman D.M., Krainc D., Duan W. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat. Med. 2012, 18:153-158.
22. Khoshnan A., Patterson P.H. The role of IkappaB kinase complex in the neurobiology of Huntington's disease. Neurobiol. Dis. 2011, 43:305-311.
23. Khoshnan A., Ko J., Watkin E.E., Paige L.A., Reinhart P.H., Patterson P.H. Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J. Neurosci. 2004, 24:7999-8008.
24. Kotrcova E., Jarkovska K., Valekova I., Zizkova M., Motlik J., Gadher S.J., Kovarova H. Challenges of Huntington's disease and quest for therapeutic biomarkers. Proteomics Clin. Appl. 2015, 9:147-158.
25. Labbadia J., Morimoto R.I. Huntington's disease: underlying molecular mechanisms and emerging concepts. Trends Biochem. Sci. 2013, 38:378-385.
26. Moumne L., Betuing S., Caboche J. Multiple aspects of gene dysregulation in Huntington's disease. Front. Neurol. 2013, 4:127.
27. Moussaud S., Draheim H.J. A new method to isolate microglia from adult mice and culture them for an extended period of time. J. Neurosci. Methods 2010, 187:243-253.
28. Ouyang W., Rutz S., Crellin N.K., Valdez P.A., Hymowitz S.G. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol. 2011, 29:71-109.
29. Politis M., Pavese N., Tai Y.F., Kiferle L., Mason S.L., Brooks D.J., Tabrizi S.J., Barker R.A., Piccini P. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum. Brain Mapp. 2011, 32:258-270.
30. Rub U., Hoche F., Brunt E.R., Heinsen H., Seidel K., Del Turco D., Paulson H.L., Bohl J., von Gall C., Vonsattel J.P., Korf H.W., den Dunnen W.F. Degeneration of the cerebellum in Huntington's disease (HD): possible relevance for the clinical picture and potential gateway to pathological mechanisms of the disease process. Brain Pathol. 2013, 23:165-177.
31. Saura J., Tusell J.M., Serratosa J. High-yield isolation of murine microglia by mild trypsinization. Glia 2003, 44:183-189.
32. Steffan J.S., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y.Z., Gohler H., Wanker E.E., Bates G.P., Housman D.E., Thompson L.M. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6763-6768.
33. Sypsa V., Touloumi G., Papatheodoridis G.V., Tassopoulos N.C., Ketikoglou I., Vafiadis I., Hatzis G., Tsantoulas D., Akriviadis E., Koutsounas S., Hatzakis A. Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. J. Viral Hepat. 2005, 12:543-550.
34. Tai Y.F., Pavese N., Gerhard A., Tabrizi S.J., Barker R.A., Brooks D.J., Piccini P. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain J. Neurol. 2007, 130:1759-1766.
35. Trager U., Andre R., Lahiri N., Magnusson-Lind A., Weiss A., Grueninger S., McKinnon C., Sirinathsinghji E., Kahlon S., Pfister E.L., Moser R., Hummerich H., Antoniou M., Bates G.P., Luthi-Carter R., Lowdell M.W., Bjorkqvist M., Ostroff G.R., Aronin N., Tabrizi S.J. HTT-lowering reverses Huntington's disease immune dysfunction caused by NFkappaB pathway dysregulation. Brain J. Neurol. 2014, 137:819-833.
36. van Kempen T.S., Wenink M.H., Leijten E.F., Radstake T.R., Boes M. Perception of self: distinguishing autoimmunity from autoinflammation. Nat. Rev. Rheumatol. 2015, 11(8):483-492.
37. Venkatraman P., Wetzel R., Tanaka M., Nukina N., Goldberg A.L. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol. Cell 2004, 14:95-104.